TVTX Travere Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Developing, manufacturing outsourced, and commercializing pharmaceutical products, including marketed drug FILSPARI and pipeline candidates
• • New emphasis on pegtibatinase Phase 3 HARMONY Study resumed in 2026 after voluntary enrollment pause in Sept 2024 due to manufacturing scale-up issues
• • Strategic reliance on third-party manufacturers with increased risks from global supply chain disruptions, tariffs, BIOSECURE Act export restrictions, and geopolitical tensions
• • Employee base and operations expanded significantly over five years, especially sales force growth to support FILSPARI commercial launch in U.S.
• • Noteworthy: The BIOSECURE Act (effective Dec 2025) imposes U.S. federal restrictions on biotechnology equipment/services from “biotechnology companies of concern,” impacting supplier relationships

Risk Factors

• • Cybersecurity risk management overseen by Nominating / Corporate Governance Committee reporting to board
• • Cybersecurity incident team with cross-functional expertise including IT, legal, compliance, and privacy functions
• • Incident response process escalates cyber incidents to executive team and board when necessary
• • Regular management reports on cybersecurity risks delivered to governance committee and board

Management Discussion & Analysis

• • Revenue specifics and YoY changes not disclosed in provided MD&A section
• • Profitability or margin figures absent; no actual % margins reported
• • Best segment: FILSPARI US approval and European market launch with $57.5M milestone payments received
• • Worst segment impact: Thiola sales affected by multiple generic approvals, leading to material adverse impact
• • Cash flow & capital allocation: $210M upfront and $25M milestone payments from bile acid assets sale; restructuring saves ~$25M annually from 2024
• • Forward outlook: FDA sNDA review for FILSPARI in FSGS continuing with April 13, 2026 PDUFA date; Phase 3 HARMONY study enrollment resumed Q1 2026 after manufacturing pause

What are the latest TVTX SEC filings in 2026?

Travere Therapeutics, Inc. (TVTX) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on May 4, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TVTX file its most recent 10-K annual report?

Travere Therapeutics, Inc. (TVTX) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TVTX 10-Q quarterly reports?

Travere Therapeutics, Inc. (TVTX)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every TVTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TVTX filed recently?

Travere Therapeutics, Inc. (TVTX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TVTX insider trading activity (Form 4)?

SignalX aggregates every TVTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TVTX file with the SEC?

Travere Therapeutics, Inc. (TVTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TVTX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Travere Therapeutics, Inc. (TVTX).

What is TVTX's SEC CIK number?

Travere Therapeutics, Inc. (TVTX)'s SEC CIK (Central Index Key) number is 1438533. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1438533 to look up all TVTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TVTX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Travere Therapeutics, Inc. (TVTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.